ATL001

BIOLOGICAL4 trials

Sponsors

Achilles Therapeutics UK Limited

Conditions

Advanced Non Small Cell Lung CancerMelanomaMetastatic or recurrent melanomaNon-small cell lung cancer

Phase 1

ATL001 in Patients With Metastatic or Recurrent Melanoma

TerminatedNCT03997474

Achilles Therapeutics UK LimitedMelanoma

Start: 2019-08-15End: 2024-09-03Updated: 2025-03-07

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

TerminatedNCT04032847

Achilles Therapeutics UK LimitedAdvanced Non Small Cell Lung Cancer

Start: 2019-07-08End: 2024-09-26Updated: 2025-03-10

An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with metastatic or recurrent melanoma

CompletedCTIS2024-513062-19-00

Achilles Therapeutics UK LimitedMetastatic or recurrent melanoma

Start: 2022-12-22End: 2024-09-17Target: 8Updated: 2024-05-06

An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer

CompletedCTIS2024-513060-26-00

Achilles Therapeutics UK LimitedNon-small cell lung cancer

Start: 2021-04-07End: 2024-09-17Target: 24Updated: 2024-06-10

Related Papers

437 Optimised achilles VELOS<sup>TM</sup> process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

Regular and Young Investigator Award Abstracts2023-10-311 citations

1312 Identification and validation of immunogenic clonal neoantigens for personalized therapies

Regular and Young Investigator Award Abstracts2023-10-31

179P Early proof of concept of safety and clinical activity of clonal neoantigen-reactive T cells (cNeT)

Immuno-Oncology Technology2022-12-012 citations

543 Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation

Regular and Young Investigator Award Abstracts2021-11-011 citations

An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).

Journal of Clinical Oncology2021-05-205 citations

Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products

Cancer Research2020-08-153 citations

Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use

Cancer Research2020-08-15